Relapsed Prostate Cancer
Conditions
Brief summary
This is an open-label, phase II trial in patients with PSA recurrence after prostatectomy. Patients entering the study will all receive initial 50 Gray (Gy) radiotherapy (25 x 2Gy) to the prostate bed and thereafter be classified as either responders or non-responders depending on PSA response at fifth week of radiotherapy. A 68-Ga- PSMA-PET is done before start of radiotherapy, and analyzed before fifth treatment week in order to identify cancer lesions in patients with poor PSA response. Patients with PSA response after 5 weeks of radiotherapy will not receive any subsequent therapy, whilst patients with poor PSA response may be in need for additional therapy such as radiotherapy to lymph node metastases and/or boost fractions to local recurrence. Patients with more than 3 lymph node metastases or distant metastases will not receive any more radiotherapy, but individualized systemic therapy will be started.
Interventions
RADIATIONExternal radiation therapy
Sponsors
Lund University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological evidence of prostate cancer in the radical prostatectomy specimen * At least 2 rising PSA values, of which the last ≥ 0.15 ng/ml * Tumor, regional nodes, metastasis (TNM): any T, N0/x, M0/x * Age: 18 years or older * World Health Organization (WHO) performance status 0-1 * Life expectancy \> 10 years * Adequate laboratory findings: hematological: hemoglobin \> 90 g/L (may be transfused to maintain or exceed this level) absolute neutrophil count (ANC) ≥ 1,0 x 109/L, platelets ≥ 75 x 109/L hepatic: bilirubin ≤ 1.5 x upper limit of normal (ULN), alanine aminotransferase (ALAT) ≤ 5 x ULN renal: creatinine ≤ 1.5 x ULN * Signed written informed consent * The patient must be able to comply with the protocol
Exclusion criteria
* Evidence of metastasis on imaging or in specimen (e.g. N1 at lymph-node dissection) * Prior or ongoing treatment with hormones (antiandrogens, GnRH) * Prior radiotherapy to the pelvis * Previous malignancy other than prostate cancer and basalioma the past 5 years. * Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) grade III-IV congestive heart failure * Severe pulmonary disease e.g. pulmonary fibrosis * Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor detection rate measured with Ga-PSMA-PET in non-responders versus responders. | PSA response is evaluated after 5 weeks of radiotherapy. Ga-PSMA-PET at baseline is compared in the PSA-responder group as compared to the non-responder group |
| Assessment of PSA response during radiotherapy. | Is evaluated once weekly during radiotherapy, duration of radiotherapy is 35 days; 70 Gy in 2 Gy fractions. |
Other
| Measure | Time frame |
|---|---|
| Assessment of PSA response post treatment. | Is evaluated at 6, 12, 24, and 60 months post-treatment. |
Countries
Sweden
Outcome results
None listed